Outlook Therapeutics (OTLK) Update / Briefing Transcript

Outlook Therapeutics (OTLK) Update / Briefing February 03, 2025 07:00 PM ET Company Participants Jennifer Kissner - Senior VP, Clinical & Regulatory AffairsJenene Thomas - CEO Jennifer Kissner The 12 week trial demonstrated that we had visual acuity improvements in both study arms across each study visits and improving greater in each at each visit. Jenene Thomas Welcome back for another Virtual Investor What This Means segment featuring Outlook Therapeutics. My name is Janine Thomas, and I am CEO of JTCIR, ...